SCHEMBL4885327

SCHEMBL4885327

O=C(Nc1ccc(-c2ccc(C(=O)[C@@H]3CCC[C@H]3C(=O)O)cc2)cc1)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 17/20 1.00
EPHX2 P34913 2/20 0.52
FPR1 P21462 1/20 0.48
FPR2 P25090 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5446047 0.98 DGAT1 (0.95) DGAT1EPHX2
SCHEMBL4893436 0.98 DGAT1 (0.95) DGAT1EPHX2
SCHEMBL4890955 0.89 DGAT1 (1.00) DGAT1EPHX2
SCHEMBL4890035 0.89 DGAT1 (1.00) DGAT1
SCHEMBL4892004 0.87 DGAT1 (0.96) DGAT1EPHX2
SCHEMBL5364648 0.87 DGAT1 (0.96) DGAT1EPHX2
SCHEMBL4888778 0.86 DGAT1 (0.81) DGAT1
SCHEMBL21995882 0.86 DGAT1 (1.00) DGAT1
SCHEMBL2742723 0.86 DGAT1 (1.00) DGAT1
SCHEMBL5372960 0.86 DGAT1 (1.00) DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080015227-A1 Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme ABBOTT LABORATORIES 2008-01-17 US claimed
WO-2007137103-A2 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2007-11-29 WO claimed
US-20080015227-A1 Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme ABBOTT LABORATORIES 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015227-A1 Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme DGAT1, DGAT2, LCAT DGAT1 1/4885EPHX2 1371/4885FPR1 2353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.